USPTO 2015–2025 USPTO PatentsView US Corporation

Abbott Molecular Inc.

USPTO PatentsView assignee record - 95 granted patents across 19 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C12Q (Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Micr).

RSS updates for this company

The verdict

According to USPTO PatentsView, Abbott ranks #3,796 of 49,997 tracked US assignees by granted-patent volume, with 95 patents across 19 technology areas.

#3,796
of 49,997 US assignees by volume
Top 33%
by Innovation Score (41.4/100)
13.7
avg claims per patent
-38%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R3796 · US Corporation #3,796 · 95 grants

GRANTS-SMALL · TOP-DECILE · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-RICH · TYPE-USCORP · VEL-DOWN · BOOK-FULL

  • GRANTS-SMALL 95 grants
  • TOP-DECILE #3,796/49,997
  • PHOTO-FINISH American Airlines
  • CPC-FOCUS C12Q · 19 areas
  • INNOV-PAR 41.4/100
  • CLAIMS-RICH 13.7 claims/avg
  • TYPE-USCORP US Corporation
  • VEL-DOWN -38% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: American Airlines, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Innovation-score neighbourhood around Abbott

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Abbott's Innovation Score is 41.4/100 (top 33% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Where Abbott's grants concentrate

Abbott Molecular Inc. is a focused PatentsView assignee: 19 CPC subclasses with 84.2% of grants classified under C12Q (Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Micr). Peak complete grant year is 2018 (18 grants) versus a trough of 1 in 2023. By volume, Abbott sits between Wi-LAN Inc. and Cortica Ltd..

Abbott's three-year grant acceleration

From 2019–2021 to 2022–2024, Abbott Molecular Inc. moved from 36 to 11 grants (0.31x the prior three-year total, a multiple, not a CAGR). See the growth leaderboard.

Who files at Abbott's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Abbott holds 95 patents at rank #3,797, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Abbott

By rank, the assignees closest to #3,797 in granted patent volume.

Leaders in C12Q (Measuring OR Testing Processes Involving Enzymes)

Other assignees with the most granted patents in Abbott's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Abbott, neither rank-band nor same-CPC leaders (those blocks stay above).

Abbott's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

41 Top 33% higher than 67% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

05101520 20152016201720182019202020212022202320242025 1
USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
Abbott Molecular Inc. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 9 9.5%
2016 11 11.6%
2017 9 9.5%
2018 18 18.9%
2019 11 11.6%
2020 14 14.7%
2021 11 11.6%
2022 6 6.3%
2023 1 1.1%
2024 4 4.2%
2025partial year 1 1.1%

Which technologies does Abbott Molecular Inc. patent most?

Top 15 of 19 technology areas

Where it ranks

Overall rank by patents

#3,796

of 49,997 tracked assignees

Innovation Score

41.4 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Abbott Molecular Inc.'s patent record in context - here's where to go next.

  • Abbott Molecular Inc.'s lead technology class is C12Q (Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Micr), 84.2% of its portfolio - see every assignee active in that class. Explore C12Q
  • Ranked #3,796 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Abbott Molecular Inc. against Wi-LAN Inc., an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 41.4/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.